Anthrone Or Anthraquinone Patents (Class 544/156)
  • Patent number: 9260408
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful for therapy or prophylaxis in a mammal, and in particular as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: February 16, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Aebi, Kurt Amrein, Benoit Hornsperger, Henner Knust, Bernd Kuhn, Yongfu Liu, Hans P. Maerki, Alexander V. Mayweg, Peter Mohr, Xuefei Tan, Mingwei Zhou
  • Patent number: 8530465
    Abstract: The invention provides a series of novel 1,2-disubstituted amido-anthraquinone derivatives. Further, the invention also provides the preparation method and application of said derivatives, said application comprises: said derivatives with therapeutically effective amount are prepared into pharmaceutical compositions for inhibition of cancer cell growth, further treating cancer.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: September 10, 2013
    Assignee: National Defense Medical Center
    Inventors: Hsu-Shan Huang, Chia-Chung Lee
  • Patent number: 8445492
    Abstract: A heteroannelated anthraquinone derivative compound is provided. The heteroannelated anthraquinone derivative compound is represented by a formula (I): wherein R1 is a substituent being one selected from a group consisting of i) a first substituent being one selected from a group consisting of a hydryl group, an amino group, a nitro group, a hydroxyl group and a cyan group, ii) a second substituent being one selected from a group consisting of (CH2)nX, a straight (CH2)n alkyl group, a (CH2)n alkoxyl group, a branched (CH2)n alkyl group, a C3˜C12 naphthenic group, and a C3˜C12 cyclic alkoxyl group, wherein 1?n?12, and X is a halogen, iii) a third substituent being one selected from a group consisting of a straight C1˜C8 alkyl group with a double-bond, a C1˜C8 alkoxyl group with a double-bond, a branched C1˜C8 alkyl group with a double-bond and a C3˜C8 naphthenic group with a double-bond, and iv) a fourth substituent of a C5˜C12 heterocyclic group.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: May 21, 2013
    Assignee: National Defense Medical Center
    Inventor: Hsu-Shan Huang
  • Patent number: 8304415
    Abstract: A series of novel 1,2-disubstituted amido-anthraquinone derivatives, and the preparation method and application of said derivatives. Said application includes said derivatives with therapeutically effective amount being prepared into pharmaceutical compositions for inhibition of cancer cell growth, further treating cancer.
    Type: Grant
    Filed: February 25, 2010
    Date of Patent: November 6, 2012
    Assignee: National Defense Medical Center
    Inventors: Hsu-Shan Huang, Chia-Chung Lee
  • Patent number: 8124799
    Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Grant
    Filed: April 20, 2009
    Date of Patent: February 28, 2012
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: Eric Anderson, Xin Jiang, Melean Visnick
  • Publication number: 20110207739
    Abstract: A series of novel 1,2-disubstituted amido-anthraquinone derivatives, and the preparation method and application of said derivatives. Said application includes said derivatives with therapeutically effective amount being prepared into pharmaceutical compositions for inhibition of cancer cell growth, further treating cancer.
    Type: Application
    Filed: February 25, 2010
    Publication date: August 25, 2011
    Inventor: Hsu-Shan HUANG
  • Patent number: 7767719
    Abstract: This invention relates compositions containing compounds of formula (I) below: Each of R1, R2, R3, R4, R5, R6, R7, and R8 is defined in the specification.
    Type: Grant
    Filed: April 9, 2007
    Date of Patent: August 3, 2010
    Assignee: SunTen Phytotech Co., Ltd.
    Inventors: Du-Shieng Chien, Yi-Wen Chu, Wu-Chang Chuang, Ming-Chung Lee
  • Publication number: 20090156807
    Abstract: Compounds for utilization as anti-tumor agents against cancer and certain inflammatory and arthritic conditions designed with multiple active sites to cause inhibition and cell death synthesized from the starting compound 1,4,5,8-tetrachloroanthraquinone. Included are anti-tumor compounds of the class 1,4,5,8-tetrakis-alkylaminoalkyl, 1,4,5,8-tetrakis-hydroxyalkylaminoalkyl, 1,4,5,8-tetrakis-chloroethylamino, 1,2-bischloroethylamino-1,4,5,8-tetrakis-aminoethylamino derivatives of Anthraquinone. Also includes mixtures of groupings such as 1-aminoalkylamino-4,5,8-tris-(1,2-dimethyl)aminoalkylamino anthraquinone, 1,2-dichloroethyl 1-aminoalkyl amino-4,5,8-tris-aminoethylamino anthraquinone, bis-1,4aminoalkylamino bis-5,8-alkylaminoanthraquinone, 1,4-bis-chloroalkylamino-5,8-bisaminoalkylamino anthraquinone and others.
    Type: Application
    Filed: October 16, 2008
    Publication date: June 18, 2009
    Inventor: D. Richard Ishmael
  • Publication number: 20080261985
    Abstract: This invention describes novel tricyclic-bis-enone derivatives (TBEs), such as TBE-31, TBE-34, TBE-45 and water-soluble TBEs. The methods of preparing these compounds are also disclosed. The inventors demonstrate the ability of these new TBEs to inhibit proliferation of human myeloma cells, inhibit the induction of iNOS in cells stimulated with interferon-?, induce heme oxygenase-1 (HO-1), induce CD11b expression—a leukemia differentiation marker, inhibit proliferation of leukemia cells, induce apoptosis in human lung cancer, and induce apoptosis in other cancerous cells. The TBEs of this invention are expected to be useful agents for the treatment and prevention of many diseases, including cancer, neurological disorders, inflammation, and pathologies involving oxidative stress.
    Type: Application
    Filed: November 16, 2007
    Publication date: October 23, 2008
    Inventors: Tadashi Honda, Chitra Sundararajan, Gordon W. Gribble, Michael B. Sporn, Karen T. Liby
  • Patent number: 7034110
    Abstract: A method for obtaining compounds having selected properties for a particular application by forming base modules having at least two structural diversity elements from the reaction of a first compound having at least one structural diversity element and a first reactive group, with a second compound having at least one structural diversity element and a second reactive group, wherein the first and second groups combine by an addition reaction; producing a first array of molecules by varying at least one of the structural diversity elements of the compounds when producing the base modules; and screening the array to determine a first suitable compound for the particular application. The base modules are preferably formed form oxazolone- and aminimide-derived compounds.
    Type: Grant
    Filed: January 23, 2004
    Date of Patent: April 25, 2006
    Assignee: ArQule, Inc.
    Inventor: Joseph C. Hogan, Jr.
  • Publication number: 20040175314
    Abstract: A method of scavenging oxygen in an atmosphere or liquid comprising the steps of: (i) treating an anthraquinone compound according to the formula: (I) wherein X1-X4 and R1-R4 are as defined in the claims, with predetermined conditions so as to reduce the anthraquinone compound to a reduced form oxidizable by oxygen; and ii) exposing the atmosphere or liquid to said compound; such that at least a portion of teh oxygen in teh atmosphere or liquid is removed through oxidation of the reduced form of the anthraquinone compound, and wherein steps i) and ii) may be carried out in either order.
    Type: Application
    Filed: May 12, 2004
    Publication date: September 9, 2004
    Inventors: Mark Andrew Horsham, Andrew David Scully, James Keith Gerard Murphy
  • Publication number: 20040077854
    Abstract: The present invention is related to sulfonamide derivatives having a lipophilic moiety and which are substantially soluble. Said compounds are notably for use as pharmaceutically active compounds. The present invention also related to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation.
    Type: Application
    Filed: October 10, 2003
    Publication date: April 22, 2004
    Inventors: Serge Halazy, Dennis Church, Stephen J. Arkinstall, Marco Biamonte, Montserrat Camps, Jean-Pierre Gotteland, Thomas Rueckle
  • Patent number: 6653307
    Abstract: The present invention provides compounds of formula I which are useful as antiviral agents, in particular, as agents against viruses of the herpes family.
    Type: Grant
    Filed: June 5, 2001
    Date of Patent: November 25, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventor: Mark E. Schnute
  • Patent number: 6566520
    Abstract: A method for the preparation and purification of compounds using a novel support, a tetrabenzo [a, c, g, i]-fluorene group (Tbf) comprising reacting a building block (A) containing a Tbf group (Tbf-A), with a second building block (B), to afford an intermediate compound (Tbg-A-B) followed by purifying the intermediate compound by adsorption on a carbon support, removing the intermediate compound from the support with a solvent and repeating the previous reactions using the required number of building blocks to synthesize the compounds followed by removal of the Tbf group to afford the desired compounds.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: May 20, 2003
    Assignee: Warner-Lambert Company
    Inventors: Sheila Helen DeWitt, Robert Ramage, Alasdair Arthur MacDonald
  • Patent number: 5436243
    Abstract: Potentiating agents inhibit the development of multidrug resistance, reduce drug-resistance in drug-resistant tumors, or sensitize tumors to antineoplastic drugs, thereby potentiating the effect of antineoplastic agents. The potentiating agents are aminoanthraquinones, preferably 1,4-bis(N-substituted) amino anthraquinones, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: November 17, 1993
    Date of Patent: July 25, 1995
    Assignees: Research Triangle Institute Duke University, Pharmaceuticals Corporation
    Inventors: Clifford W. Sachs, Robert L. Fine, Lawrence M Ballas, R. Ivy Carroll, Robert Bell
  • Patent number: 5174913
    Abstract: A corrosion inhibitor with excellent film forming and film persistency characteristics may be produced by first reacting in a condensation reaction a polybasic acid with a polyalcohol to form a partial ester. The partial ester is reacted with imidazoline and/or fatty diamines to salt the ester. If warranted, the salted partial ester may be reacted with a metal hydroxide, a metal oxide, and/or ammonia to further salt the ester. Surfactants may be added to tailor the inhibitor formulation to meet the specific needs of the user (i.e., the corrosion inhibitor may be formulated to produce an oil-soluble, highly water-dispersible corrosion inhibitor or an oil-dispersible, water-soluble corrosion inhibitor). Suitable carrier solvents may be employed where needed to effectively disperse the corrosion inhibitor formulation.
    Type: Grant
    Filed: September 20, 1991
    Date of Patent: December 29, 1992
    Assignee: Westvaco Corporation
    Inventors: John A. Alford, Paul G. Boyd, Eugene R. Fischer
  • Patent number: 4950756
    Abstract: 1-Nitroanthraquinone-2-carboxylic acid of the formula I ##STR1## is prepared by treating novel 2-substituted 1-nitroanthraquinones of the general formula II ##STR2## where R is --CH.dbd.CH--R.sup.1 or --CH.sub.2 --CHO, where R.sup.1 is C.sub.1 -C.sub.5 -dialkylamino or a cyclic 5- or 6-membered amine which may contain further hetero atoms, with oxidizing agents free of heavy metal.
    Type: Grant
    Filed: October 30, 1989
    Date of Patent: August 21, 1990
    Assignee: BASF Aktiengesellschaft
    Inventors: Jochem Henkelmann, Helmut Hoch, Thomas-Michael Kahl, Gerhard Kilpper, Walter Maier
  • Patent number: 4894451
    Abstract: The disclosure describes unsymmetrical 1,4-bis-(aminoalkylamino)-anthracene-9,10-diones useful in the treatment of neoplasms. Also described is a process of preparing same starting from 1,4-dimethoxyanthracene-9,10-dione which is reacted with an aminoalkylamine. The reaction product is treated with a dialkylaminoethylamine or a N-heteroethylamine to give the unsymmetrical compound.
    Type: Grant
    Filed: July 19, 1988
    Date of Patent: January 16, 1990
    Assignee: The University of Vermont
    Inventors: A. Paul Krapcho, Miles P. Hacker, John J. Landi, Jr., J. J. McCormack, Kenneth J. Shaw
  • Patent number: 4782092
    Abstract: Chemical compounds are provided that are novel 5,8-dichloro-4-hydroxy-1-[(aminoalkyl)amino]-9,10-anthracenediones (I), as well as a method for their production, pharmaceutical compositions comprising the compounds, and methods of treatment using the compounds in dosage form. Compounds of the invention have pharmacological properties and are useful antimicrobial agents and antitumor agents.
    Type: Grant
    Filed: July 3, 1986
    Date of Patent: November 1, 1988
    Assignee: Mid-America Cancer Center
    Inventors: Robert K. Zee-Cheng, Chia C. Cheng
  • Patent number: 4540519
    Abstract: This disclosure describes symmetrical 1,4-bis-(substituted-amino)-5,8-hydroxyanthraquinones useful as chelating agents and for inducing regression and/or palliation of cancer diseases in mammals.
    Type: Grant
    Filed: April 9, 1984
    Date of Patent: September 10, 1985
    Assignee: American Cyanamid Company
    Inventors: Keith C. Murdock, Frederick E. Durr
  • Patent number: 4517183
    Abstract: The present invention provides pharmaceutical compositions containing N-substituted aziridine-2-carboxylic acid derivatives of the general formula: ##STR1## wherein X is a carboxyl, a cyano, an alkoxycarbonyl or an optionally substituted carbamoyl radical, R is a hydrogen atom, an aliphatic hydrocarbon radical which is saturated or can contain one or more unsaturations and can be substituted one or more times by halogen, alkoxy, hydroxyl, dialkylamino, dialkylaminoxy, cycloalkylamino, acylamino, acyl, nitro, alkylthio, alkylsulphinyl, alkylsulphonyl, cyano, carboxyl, alkoxycarbonyl or carbamoyl or by cycloalkyl or cycloalkenyl radicals optionally carrying alkyl, alkoxy or alkoxycarbonyl radicals, optionally interrupted by hetero atoms and optionally bridged, or by an aryl, hetaryl, aryloxy, arylthio, acyloxy, alkoxycarbonylamino or isothioureido radical, or R is a cycloalkyl or cycloalkenyl radical optionally substituted by alkyl, alkoxy or oxo groups, optionally interrupted by hetero atoms and optionally bri
    Type: Grant
    Filed: May 17, 1983
    Date of Patent: May 14, 1985
    Assignee: Boehringer Mannheim GmbH
    Inventors: Elmar Bosies, Wolfgang Kampe, Max Thiel, Uwe Bicker, Dietmar Boerner
  • Patent number: 4374984
    Abstract: Compounds of the formula ##STR1## wherein the substituents A, Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, X, n and m are defined hereinbeloware effective photoinitiators, especially for the photopolymerization of ethylenically unsaturated compounds and for the curing of printing inks.
    Type: Grant
    Filed: March 4, 1981
    Date of Patent: February 22, 1983
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Jurgen Eichler, Claus Herz, Karl-Heinz Neisius, Gregor Wehner